Fig. 1
From: Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer
SLC6A1 overexpression significantly associates with aggressive progression and poor prognosis in patients with prostate cancer (a). A full view of the immunohistochemistry staining and HE staining for SLC6A1 in our TMA cohort. b Immunostaining of highSLC6A1 expression and low SLC6A1expression. Magnification of the right panel is × 5; the left panel is × 20. c Immunoreativity score (IRS) of SLC6A1 expression in the benign group and the cancer group. There was a obvious difference in SLC6A1 expression between two groups(P = 0.004). d There was a significant difference in BCR-free survival between patients with high and low SLC6A1 mRNA expression in TCGA database (P = 0.002). e There was also a significant difference in BCR-free survival between patients with high and low SLC6A1 mRNA expression in Taylor database (P = 0.026)